Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OUTREACH2: MTL-CEBPA plus sorafenib versus sorafenib alone in previously treated advanced hepatocellular carcinoma with hepatitis B or C
NL-OMON51314Phase 2Not yet recruiting
- Sponsor
- Mina Alpha Limited
- Start
- Jun 2022
- Modality
- Small Molecules, Gene Therapies, Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC), hepatitis B (HBV) and hepatitis C virus infection comparing MTL-CEBPA + sorafenib with sorafenib monotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
MTL-CEBPAsorafenib
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON51314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51314.